[1]
Basappa, N.S. 2016. Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Canadian Urological Association Journal. 10, 11-12 (Dec. 2016), S242–4. DOI:https://doi.org/10.5489/cuaj.4292.